Other languages Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
107.2 ^USD	+0.18%		+15.26%	+16.21%

02/05	Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating	MT
02/05	Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	02/05
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024	02/05
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	23/03
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	02/03
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety	23/02
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	23/02
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	22/02
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	15/02
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	15/02
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024	15/02
Blueprint Medicines Insider Sold Shares Worth $395,350, According to a Recent SEC Filing	14/12
Blueprint Medicines Receives European Approval for Ayvakyt in Indolent Systemic Mastocytosis	12/12
Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis	12/12
Blueprint Medicines Insider Sold Shares Worth $375,000, According to a Recent SEC Filing	12/12
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted At 2023 Ash Annual Meeting	09/12
Blueprint Medicines Insider Sold Shares Worth $352,750, According to a Recent SEC Filing	05/12
Blueprint Medicines Insider Sold Shares Worth $1,012,690, According to a Recent SEC Filing	29/11
Blueprint Medicines Gets Positive CHMP Opinion For Indolent Systemic Mastocytosis	11/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Other languages

Filters